News | November 16, 2024
IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Total Income in Q2 FY25 stood at Rs. 532.18 crore
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Donation drive in São Paulo aims to support 250 young women’s health and environmental responsibility
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Subscribe To Our Newsletter & Stay Updated
